Research peptides: complete guide to mechanisms, categories, and evidence

Research peptides are short amino acid sequences — typically 2 to 50 residues — that exert biological activity through specific receptor binding, enzyme modulation, or intracellular signalling interactions. The term distinguishes compounds that have preclinical or early clinical data supporting biological activity from approved pharmaceuticals that have completed the full regulatory pathway to clinical use.

This guide provides a comprehensive, mechanism-organised reference across all major categories of research peptides covered on this site. Each section links to the detailed article for each compound and situates it within its mechanistic category.

How to use this guide

Evidence quality is indicated throughout using a simple framework:

• Preclinical only: Animal or in vitro data; no clinical trials
• Early clinical: Phase I/II safety data or small clinical studies
• Clinical evidence: Randomised controlled trial data in humans

Tissue repair and regeneration peptides

BPC-157

Mechanism: 15-amino acid sequence derived from gastric juice. Upregulates growth hormone receptor expression, modulates nitric oxide synthesis, and interacts with the FAK-paxillin signalling pathway governing cell migration and fibroblast activity.

Evidence: Preclinical only. Extensive rodent data across tendon, ligament, muscle, bone, and gut healing models.

Full coverage: BPC-157 tissue repair mechanisms

TB-500 / Thymosin beta-4

Mechanism: G-actin sequestration maintaining the monomeric actin pool for cytoskeletal reorganisation during injury. Additionally activates HIF-1α/VEGF angiogenesis and inhibits NF-κB inflammatory signalling.

Evidence: Preclinical + early clinical (Phase II pressure ulcer trial). WADA prohibited substance.

Full coverage: Thymosin beta-4 tissue repair

GHK-Cu

Mechanism: Endogenous tripeptide-copper complex that stimulates collagen and glycosaminoglycan synthesis, activates metalloproteinases for ECM remodelling, and upregulates superoxide dismutase. Skin levels decline markedly with age.

Full coverage: GHK-Cu collagen and wound healing

KPV

Mechanism: C-terminal tripeptide of alpha-MSH. Binds MC1R and directly inhibits NF-κB nuclear translocation in intestinal epithelial cells and macrophages.

Full coverage: KPV anti-inflammatory science

---

Growth hormone secretagogue peptides

CJC-1295 / Ipamorelin

Mechanism: CJC-1295 is a GHRH analogue; ipamorelin is a selective GHSR-1a agonist. Used together they act synergistically at both GH release axes without the cortisol or prolactin elevations of older GHRPs.

Evidence: Preclinical + early clinical (CJC-1295 Phase II in healthy adults).

Full coverage: CJC-1295 Ipamorelin synergy

Full class overview: Growth hormone secretagogues science

---

Cognitive enhancement and neuroprotective peptides

Semax

Mechanism: Heptapeptide ACTH(4-7) analogue. Upregulates BDNF and TrkB, activates serotonin and dopamine receptor expression. Approved in Russia and Ukraine for neurological conditions.

Evidence: Preclinical + Russian clinical data. No Western RCT data.

Full coverage: Semax and BDNF cognitive enhancement

Selank

Mechanism: Tuftsin analogue. Modulates GABAergic transmission via partial benzodiazepine receptor agonism, reduces anxiety-associated neurochemical patterns. Registered in Russia for anxiety disorders.

Full coverage: Selank anxiolytic mechanisms

Dihexa

Mechanism: Angiotensin IV analogue that potentiates HGF/MET receptor signalling, driving synaptogenesis in hippocampal neurons. Claimed high potency in synaptogenesis assays relative to BDNF (single-group data).

Evidence: Preclinical only. No clinical trials.

Full coverage: Dihexa hepatocyte growth factor signalling

---

Metabolic and weight regulation peptides

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide)

Mechanism: Incretin mimetics activating GLP-1R in pancreatic beta cells (glucose-dependent insulin secretion), gastric smooth muscle (delayed emptying), and hypothalamic neurons (appetite suppression).

Evidence: Clinical — approved medications with extensive Phase III data and MACE cardiovascular outcomes trial evidence.

Full coverage: GLP-1 receptor agonists explained | GLP-1 cardiovascular outcomes | Semaglutide weight loss mechanisms

Tirzepatide and retatrutide

Dual (GIP/GLP-1) and triple (GIP/GLP-1/glucagon) receptor agonists with additive metabolic benefits at each additional receptor target.

Full coverage: Tirzepatide dual agonism | Retatrutide triple receptor agonism

---

Mitochondrial peptides

SS-31 (Elamipretide)

Mechanism: Szeto-Schiller tetrapeptide that selectively concentrates in the inner mitochondrial membrane, binds cardiolipin, reduces cardiolipin peroxidation, restores cristae morphology, and reduces mitochondrial ROS.

Evidence: Preclinical + clinical (Phase II/III in heart failure and Barth syndrome).

Full coverage: SS-31 mitochondrial cardiolipin

MOTS-c

Mechanism: Mitochondrial-derived peptide encoded in the 12S rRNA gene. Activates AMPK in skeletal muscle, improves insulin sensitivity, reduces adiposity, extends lifespan in aged mice. Circulating levels decline with age.

Full coverage: MOTS-c metabolic adaptation

Humanin and SHLPs

Mechanism: Mitochondrial-derived peptides encoded in the 16S rRNA gene. Humanin inhibits BAX-mediated apoptosis via the CNTFR/WSX-1/gp130 receptor complex. SHLP2/3 are cytoprotective; SHLP6 shows pro-apoptotic activity in cancer lines.

Full coverage: Humanin and SHLP mitochondrial peptides

Full mitochondrial overview: Mitochondrial peptides research overview

---

Longevity and anti-ageing peptides

Senolytic peptides (FOXO4-DRI, BH3 mimetics)

Mechanism: Selectively clear senescent cells. FOXO4-DRI disrupts the FOXO4–p53 pro-survival interaction specific to senescent cells. BH3 mimetics occupy the BCL-2/BCL-XL hydrophobic groove to release sequestered pro-apoptotic effectors.

Evidence: Preclinical — aged mice showing lifespan extension, restored physical function, reduced senescent cell burden.

Full coverage: Senolytic peptides and cellular senescence

Epitalon

Mechanism: Tetrapeptide (Ala-Glu-Asp-Gly) proposed to upregulate telomerase (hTERT) expression and restore pineal melatonin secretion. Developed by the Khavinson group.

Evidence: Preclinical lifespan extension data + Russian clinical data in elderly cohorts. Independent replication limited.

Full coverage: Epitalon telomere longevity research

Yamanaka factor partial reprogramming

Mechanism: Transient sub-pluripotency OSKM expression reverses epigenetic ageing markers via TET-mediated active DNA demethylation, while preserving cell identity. Cyclic administration extends lifespan in progeroid mice.

Evidence: Preclinical only. Major commercial development (Altos Labs); no clinical data.

Full coverage: Yamanaka factors and partial reprogramming

Epigenetic clocks and peptide interventions

Covers the Horvath DNAm clock, GrimAge, and PhenoAge — and evidence for peptide interventions measurably reducing biological age.

Full coverage: Epigenetic clocks and peptide interventions

---

Peptide bioregulators

Thymalin and thymosin alpha-1

Thymic peptides addressing immunosenescence. Thymosin alpha-1 has clinical evidence in hepatitis B (RCT meta-analysis) and sepsis (multi-centre RCT). Thymalin has suggestive longevity data from Russian cohort studies requiring independent replication.

Full coverage: Thymalin and thymosin alpha-1

Full bioregulator overview: Peptide bioregulators overview

---

NAD+ and sirtuin pathway

The NAD+/sirtuin signalling axis intersects with multiple peptide mechanisms — mitochondrial function, insulin resistance, SASP regulation, and epigenetic ageing — and represents a key hub in longevity biology.

Full coverage: NAD+ and sirtuin longevity pathways

---

Melanocortin peptides

PT-141 (Bremelanotide)

MC4R agonist acting on hypothalamic circuits governing sexual arousal. FDA-approved as Vyleesi — one of the few research-origin peptides to achieve regulatory approval.

Full coverage: PT-141 melanocortin pathway

---

Evidence quality considerations

Species translation: Rodent data does not predictably translate to humans. Rodent metabolism and lifespan differ substantially from human physiology.

Single-group replication: Several foundational findings originate from single research groups. Independent replication substantially increases confidence.

Outcome endpoint quality: Surrogate markers (epigenetic clock scores, IGF-1 levels) may or may not translate to clinically meaningful outcomes. Hard endpoints — mortality, disease incidence, functional capacity — carry more evidential weight.

Regulatory status: All compounds in this guide not explicitly marked as approved are research compounds not approved by the TGA or FDA for human therapeutic use.

---

For an introduction to research peptides and the regulatory framework, see the what are research peptides overview.